Danaher (NYSE:DHR) Price Target Lowered to $260.00 at Jefferies Financial Group

Danaher (NYSE:DHR) had its price target decreased by equities research analysts at Jefferies Financial Group from $285.00 to $260.00 in a report issued on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the conglomerate’s stock. Jefferies Financial Group’s target price would suggest a potential upside of 16.53% from the stock’s previous close.

A number of other equities research analysts have also weighed in on the company. Scotiabank began coverage on Danaher in a research report on Monday, December 23rd. They set a “sector perform” rating and a $265.00 target price for the company. Barclays cut their price target on Danaher from $285.00 to $275.00 and set an “equal weight” rating on the stock in a report on Wednesday, October 23rd. Evercore ISI lifted their price target on Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Stifel Nicolaus boosted their target price on Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a research note on Wednesday, October 23rd. Finally, Stephens reiterated an “overweight” rating and set a $315.00 price target on shares of Danaher in a research note on Wednesday, October 23rd. Six equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $284.14.

Danaher Price Performance

Shares of NYSE:DHR traded down $24.72 during trading on Wednesday, hitting $223.12. 11,388,171 shares of the company’s stock were exchanged, compared to its average volume of 3,455,745. The company has a market cap of $161.15 billion, a price-to-earnings ratio of 42.58, a PEG ratio of 4.43 and a beta of 0.83. The business’s 50-day simple moving average is $236.09 and its 200 day simple moving average is $253.66. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. Danaher has a 52-week low of $223.00 and a 52-week high of $281.70.

Danaher (NYSE:DHR) last announced its earnings results on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, hitting analysts’ consensus estimates of $2.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. During the same period in the previous year, the business posted $2.09 earnings per share. As a group, equities analysts predict that Danaher will post 7.5 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. FMR LLC lifted its holdings in Danaher by 15.8% during the 3rd quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock worth $6,566,116,000 after buying an additional 3,217,631 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in Danaher by 3.0% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,097,986 shares of the conglomerate’s stock valued at $1,417,342,000 after acquiring an additional 148,251 shares during the period. Fisher Asset Management LLC increased its position in Danaher by 2.6% in the 3rd quarter. Fisher Asset Management LLC now owns 4,552,640 shares of the conglomerate’s stock valued at $1,265,725,000 after acquiring an additional 116,299 shares during the period. Massachusetts Financial Services Co. MA increased its position in Danaher by 17.6% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock valued at $996,141,000 after acquiring an additional 535,254 shares during the period. Finally, Montrusco Bolton Investments Inc. increased its position in Danaher by 0.6% in the 4th quarter. Montrusco Bolton Investments Inc. now owns 1,715,826 shares of the conglomerate’s stock valued at $382,936,000 after acquiring an additional 9,942 shares during the period. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.